Relationship between malignancies and autoimmunity. A literature review and analysis of a clinical case

Main Article Content

Ye.D. Yehudina
O.O. Dyadyk
S.A. Tripilka
S.Kh. Ter-Vartanіan

Abstract

There is a complex bidirectional relationship between rheumatic diseases and cancer. Certain rheumatic diseases, in particular dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, and systemic sclerosis, on the one hand, are associated with an increased risk of malignant neoplasms against the background of the disease, contributing to cancer due to immunological stimulation. On the other hand, it can manifest as a result of autoimmune reactions caused by primary cancer in the form of paraneoplastic syndrome. Paraneoplastic syndrome is a symptom or set of symptoms that are secondary to the primary cancer process. These symptoms can result from substances secreted by the tumor (hormones and other biologically active substances) or due to the immune reaction to tumor cells (autoimmune reactions, the formation of immune complexes, suppression of the immune system), involving various organs and systems distant from the primary focus or metastases. This paper presents a literature review about the relationship between autoimmune diseases, to a greater extent systemic lupus erythematosus, and malignant neoplasms, and a clinical case in which the manifestation of lupus nephritis coincided with the detection of papillary thyroid carcinoma.

Article Details

How to Cite
Yehudina, Y., O. Dyadyk, S. Tripilka, and Ter-Vartanіan S. “Relationship Between Malignancies and Autoimmunity. A Literature Review and Analysis of a Clinical Case”. KIDNEYS, vol. 10, no. 2, July 2021, pp. 70-77, doi:10.22141/2307-1257.10.2.2021.234322.
Section
To Help the Practitioner

References

Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015 Feb;67(2):317-326. doi:10.1002/art.38928.

Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis. 2018 Apr;77(4):510-514. doi:10.1136/annrheumdis-2017-212086.

Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014 Jan;73(1):138-142. doi:10.1136/annrheumdis-2012-202099.

Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi:10.1136/annrheumdis-2016-210708.

Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819.

Manzia TM, Angelico R, Gazia C, et al. De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature. World J Gastroenterol. 2019 Sep 21;25(35):5356-5375. doi:10.3748/wjg.v25.i35.5356.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-545. doi:10.1016/S0140-6736(00)04046-0.

Ljung R, Talbäck M, Haglund B, et al. Cancer incidence in Sweden 2015. Stockholm: National Board of Health and Welfare; 2017.

Mao S, Shen H, Zhang J. Systemic lupus erythematosus and malignancies risk. J Cancer Res Clin Oncol. 2016 Jan;142(1):253-262. doi:10.1007/s00432-015-2032-0.

Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013 May;42:130-135. doi:10.1016/j.jaut.2012.12.009.

Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008 Oct;19(8):887-894. doi:10.1007/s10552-008-9151-8.

Bernatsky S, Boivin JF, Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005 Oct 15;53(5):781-784. doi:10.1002/art.21458.

Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus. 2009 May;18(6):479-485. doi:10.1177/0961203309102556.

Löfström B, Backlin C, Sundström C, Hellström-Lindberg E, Ekbom A, Lundberg IE. Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. Rheumatology (Oxford). 2009 Oct;48(10):1222-1226. doi:10.1093/rheumatology/kep204.

King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol. 2007 Sep;26(9):1491-1494. doi:10.1007/s10067-006-0532-7.

Antonelli A, Mosca M, Fallahi P, et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab. 2010 Jan;95(1):314-318. doi:10.1210/jc.2009-0677.

Lancaster E. Paraneoplastic Disorders. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1653-1679. doi:10.1212/CON.0000000000000542.

Szekanecz E, András C, Sándor Z, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev. 2006 Nov;6(1):42-47. doi:10.1016/j.autrev.2006.03.007.

Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134. doi:10.1097/01.bor.0000209423.39033.94.

Hidalgo-Conde A, de Haro Liger M, Abarca-Costalago M, et al. Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus. Reumatol Clin. 2013 Nov-Dec;9(6):359-364. doi:10.1016/j.reuma.2012.10.015.

Most read articles by the same author(s)

1 2 > >>